Biologic Agents for Periodontal Regeneration and Implant Site Development.
The advancement of molecular mediators or biologic agents has increased tremendously during the last decade in periodontology and dental implantology. Implant site development and reconstruction of the lost periodontium represent main fields in which these molecular mediators have been employed and investigated. Different growth factors trigger different reactions in the tissues of the periodontium at various cellular levels. Proliferation, migration, and differentiation constitute the main target areas of these molecular mediators. It was the purpose of this comprehensive review to describe the origin and rationale, evidence, and the most current understanding of the following biologic agents: Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB), Enamel Matrix Derivate (EMD), Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF), Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2), Bone Morphogenic Proteins (BMPs, BMP-2 and BMP-7), Teriparatide PTH, and Growth Differential Factor-5 (GDF-5).
Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Fernando
F
Suárez-López Del Amo
Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Alberto
A
Monje
Department of Oral Surgery and Implant Dentistry, University of Granada, Granada, Spain.
Miguel
M
Padial-Molina
2nd Clinical Division, Peking University School of Stomatology, Beijing, China.
ZhiHui
Z
Tang
Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Hom-Lay
HL
Wang
D000077214:Becaplermin; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use; D003746:Dental Enamel Proteins / Q000627:therapeutic use; D015921:Dental Implants; D055428:Growth Differentiation Factor 5 / Q000627:therapeutic use; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods / Q000639:trends*; D006801:Humans; D010519:Periodontium / Q000187:drug effects / Q000254:growth & development* / Q000473:pathology; D053657:Platelet-Rich Plasma / Q000378:metabolism; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use*
D019485:Bone Morphogenetic Proteins; D003746:Dental Enamel Proteins; D015921:Dental Implants; D055428:Growth Differentiation Factor 5; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; C109069:enamel matrix proteins; D000077214:Becaplermin